EZH2 and neoplasm: Thyroid hormone-mediated EZH2 inhibition reduces H3K27me3 histone marks at NEUROD1 regulatory regions and enhances NEUROD1 expression, eventually driving tumor cell differentiation into postmitotic cells and suppressing MB growth irreversibly (43, 177).